226 related articles for article (PubMed ID: 11684864)
21. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
[TBL] [Abstract][Full Text] [Related]
22. Assessment and management of high-risk pregnancies in women with thrombophilia.
Sarig G; Vidergor G; Brenner B
Blood Rev; 2009 Jul; 23(4):143-7. PubMed ID: 19135285
[TBL] [Abstract][Full Text] [Related]
23. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
[TBL] [Abstract][Full Text] [Related]
24. Laboratory monitoring of thromboprophylaxis with low molecular weight and standard heparin.
Vukovich T; Proidl S; Teufelsbauer H; Kautzky A; Erlacher L; Luger A; Weissel M
Thromb Res; 1992 Jun; 66(6):735-43. PubMed ID: 1519232
[TBL] [Abstract][Full Text] [Related]
25. Prospective evaluation of coagulation activation in pregnant women receiving low-molecular weight heparin.
Hoke M; Kyrle PA; Philipp K; Pabinger I; Kaider A; Schönauer V; Quehenberger P; Eichinger S
Thromb Haemost; 2004 May; 91(5):935-40. PubMed ID: 15116254
[TBL] [Abstract][Full Text] [Related]
26. Thromboprophylaxis implementation during pregnancy in women with recurrent foetal losses and thrombophilia.
Mitić G; Novakov Mikić A; Povazan L; Mitreski A; Kopitović V; Vejnović T
Med Pregl; 2011; 64(9-10):471-5. PubMed ID: 22097113
[TBL] [Abstract][Full Text] [Related]
27. Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study.
Norris LA; Bonnar J; Smith MP; Steer PJ; Savidge G
Thromb Haemost; 2004 Oct; 92(4):791-6. PubMed ID: 15467910
[TBL] [Abstract][Full Text] [Related]
28. Markers of hemostatic system activation during treatment of deep vein thrombosis with subcutaneous unfractionated or low-molecular weight heparin.
Peternel P; Terbizan M; Tratar G; Bozic M; Horvat D; Salobir B; Stegnar M
Thromb Res; 2002 Feb; 105(3):241-6. PubMed ID: 11927130
[TBL] [Abstract][Full Text] [Related]
29. [Prevention of venous thromboembolism with heparin in risk patients during pregnancy: monitoring by measuring thrombin-antithrombin III complex].
von Felten A
Ther Umsch; 1992 Dec; 49(12):837-42. PubMed ID: 1485282
[TBL] [Abstract][Full Text] [Related]
30. [Improved postoperative prevention of thrombosis in trauma surgery by dose adjusted low molecular weight heparin based on TAT and D-dimer values].
Hansen M; Mayer A; Peetz D; Hafner G; Prellwitz W; Rommens PM
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1213-7. PubMed ID: 9931839
[No Abstract] [Full Text] [Related]
31. Thrombin formation and effect of unfractionated heparin during pediatric cardiac catheterization.
Chen D; Långström S; Petäjä J; Heikinheimo M; Pihkala J
Catheter Cardiovasc Interv; 2013 Jun; 81(7):1174-9. PubMed ID: 22915548
[TBL] [Abstract][Full Text] [Related]
32. The assay of overall haemostasis potential used to monitor the low molecular mass (weight) heparin, dalteparin, treatment in pregnant women with previous thromboembolism.
Antovic A; Blombäck M; Bremme K; He S
Blood Coagul Fibrinolysis; 2002 Apr; 13(3):181-6. PubMed ID: 11943930
[TBL] [Abstract][Full Text] [Related]
33. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin.
Pettilä V; Leinonen P; Markkola A; Hiilesmaa V; Kaaja R
Thromb Haemost; 2002 Feb; 87(2):182-6. PubMed ID: 11858475
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis.
Harenberg J; Huck K; Bratsch H; Stehle G; Dempfle CE; Mall K; Blauth M; Usadel KH; Heene DL
Haemostasis; 1990; 20 Suppl 1():205-19. PubMed ID: 1964663
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy.
Ní Ainle F; Wong A; Appleby N; Byrne B; Regan C; Hassan T; Milner M; Sullivan AO; White B; O'Donnell J
Blood Coagul Fibrinolysis; 2008 Oct; 19(7):689-92. PubMed ID: 18832911
[TBL] [Abstract][Full Text] [Related]
36. Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss.
Sarig G; Blumenfeld Z; Leiba R; Lanir N; Brenner B
Thromb Haemost; 2005 Nov; 94(5):980-5. PubMed ID: 16363240
[TBL] [Abstract][Full Text] [Related]
37. Markers of hemostatic system activation in acute deep venous thrombosis-evolution during the first days of heparin treatment. The DVTENOX Study Group.
Thromb Haemost; 1993 Dec; 70(6):909-14. PubMed ID: 8165610
[TBL] [Abstract][Full Text] [Related]
38. [Prevention of thromboembolism in trauma surgery by dose adjustment of low molecular weight heparin depending on levels of TAT and D-dimer].
Mayer A; Hansen M; Peetz D; Hafner G; Vogel N; Prellwitz W; Rommens PM
Unfallchirurg; 2003 Dec; 106(12):1020-8. PubMed ID: 14727038
[TBL] [Abstract][Full Text] [Related]
39. Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis.
Fox NS; Laughon SK; Bender SD; Saltzman DH; Rebarber A
Obstet Gynecol; 2008 Oct; 112(4):884-9. PubMed ID: 18827132
[TBL] [Abstract][Full Text] [Related]
40. [Monitoring of low-molecular-weight heparins in pregnant women with inherited thrombophilic disorders].
Paskaleva I; Karagiozova Zh; Doncheva E; Dineva D
Akush Ginekol (Sofiia); 2014; 53(2):3-10. PubMed ID: 25098102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
